Clinical Trials & Results

Search or filter the listing below to find a trial or results of a completed trial.

View Actively Recruiting Clinical Trials

Click here to see trials currently recruiting participants

Filter

Health Condition

Toggle

Study Status

Toggle

Age group

Toggle

Gender

Toggle

Phase

Toggle

Study Types

Toggle

All Results

No results found

Please change the filter settings to find the product(s) you are looking for. You can also use the search function to look up a product.

Clear Filters

Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for Episodic Migraine

headache-icon.png
Condition(s):
Migraine
Status:
Completed
Requirements:
18 Years to 70 Years
Interventions:
Drug: Fremanezumab | Drug: Placebo
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Efficacy and Safety of 2 Doses of TEV-48125 Versus Placebo for the Prevention of Chronic Migraine

headache-icon.png
Condition(s):
Migraine
Status:
Completed
Requirements:
18 Years to 70 Years
Interventions:
Drug: Fremanezumab | Drug: Placebo
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Efficacy and Safety of Subcutaneous Administration of Fremanezumab for Migraine

headache-icon.png
Condition(s):
Migraine
Status:
Completed
Requirements:
18 Years to 70 Years
Interventions:
Drug: Fremanezumab | Drug: Placebo
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Fremanezumab Compassionate Use Program for Pediatric Patients With Migraine

headache-icon.png
Condition(s):
Migraine
Status:
Available
Requirements:
6 Years to 17 years
Interventions:
Drug: Fremanezumab
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Fremanezumab in Preventing Episodic Migraine in Patients 6 to 17 Years of Age

headache-icon.png
Condition(s):
Migraine
Status:
Completed
Requirements:
6 Years to 17 Years
Interventions:
Drug: Fremanezumab | Drug: Placebo
Learn more Primary objectives: The primary objective of the study is to evaluate the efficacy of fremanezumab as compared to placebo for the preventive treatment of episodic migraine (EM). Secondary objectives: Secondary objectives are to further demonstrate the efficacy of Fremanezumab as compared to placebo for the preventive treatment of EM, to evaluate the safety and tolerability of Fremanezumab in the preventive treatment of EM and to evaluate the immunogenicity of Fremanezumab and the impact of antidrug antibodies (ADAs) on clinical outcomes in participants exposed to Fremanezumab. The total duration of the study is planned to be up to 51 months

Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Patients 6 to 17 Years

headache-icon.png
Condition(s):
Migraine
Status:
Completed
Requirements:
6 Years to 17 Years
Interventions:
Drug: Fremanezumab | Drug: Placebo
Learn more Primary objectives: The primary objective of the study is to evaluate the effectiveness of fremanezumab as compared to placebo for the preventive treatment of chronic migraine (CM). The secondary objectives: Secondary objectives are to further demonstrate the efficacy of Fremanezumab as compared to placebo for the preventive treatment of CM, to evaluate the safety and tolerability of Fremanezumab in the preventive treatment of CM and to evaluate the immunogenicity of Fremanezumab and the impact of antidrug antibodies (ADAs) on clinical outcomes in participants exposed to Fremanezumab The total duration of the study is planned to be 48 months.

Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

headache-icon.png
Condition(s):
Migraine
Status:
Active, not recruiting
Requirements:
6 Years to 17 Years
Interventions:
Drug: Fremanezumab
Learn more Primary objectives: The primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment in the pivotal study). Secondary objectives: Secondary objectives are to evaluate the efficacy of subcutaneous fremanezumab in pediatric participants with migraine and to evaluate the immunogenicity of fremanezumab and the impact of ADAs on clinical outcomes in pediatric participants exposed to fremanezumab. The total duration of the study is planned to be up to 60 months.